HOME >> BIOLOGY >> NEWS
Delivering the fruits of biotechnology to the developing world: Institute for Global Health sponsors global health forum, February 18-21

Leaders from governments, biotechnology companies, and multi-lateral agencies from around the world will gather in Carmel Valley, CA, February 18-21 to study how best to promote development of drugs and vaccines for the world's poorest countries. This Global Health Forum: "Creating Global Markets for Orphan Drugs & Vaccines: A Challenge for Public/Private Partnership," will be sponsored by the Institute for Global Health, of the University of California, San Francisco, and UC Berkeley.

Although the forum is closed to the press and the public, its participants will publish a set of conclusions and recommendations for action. They will discuss these recommendations at a press briefing in San Francisco, Tuesday, February 22.

As the biotechnology and vaccine industries have blossomed in recent decades, they have focused predominantly on diseases affecting the world's richest countries. Diseases that plague poor countries, such as malaria and sleeping sickness, have been largely ignored, said Dr. Richard Feachem, PhD, DSc(Med), founding director of the Institute for Global Health, and a professor of international health at UCSF and UC Berkeley.

"Modern biomedical science and biotechnology are beginning to deliver fantastically powerful new drugs and new vaccines. We must find ways to bring the fruits of medical science to all people in the world who could benefit from them. If we fail, the consequences will be catastrophic," he said.

Without a more concerted effort, the epidemics developing countries are now facing will reach catastrophic proportions, Feachem said. "In a few years, malaria will be untreatable, and HIV will have caused devastation in Asia as it has already in Africa," he said. Malaria parasites are quickly becoming resistant and there are no new drugs in the development pipeline, and HIV vaccines that low income countries can afford and use are still years away, he

Several public/private partnerships targeting individual diseas
'"/>

Contact: Kevin Boyd
kboyd@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
6-Feb-2000


Page: 1 2 3

Related biology news :

1. More people are getting sick from eating fresh fruits
2. Middle-aged women who consume many fruits and vegetables are at much lower risk of cardiovascular disease
3. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
4. UK biotechnology business plan competition now open to students in the US and Canada
5. Plants for the future: A European vision for plant biotechnology towards 2025
6. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
7. Poll: NY residents split on biotechnology in food and agriculture
8. First company founded on UCF biotechnology formed
9. NASA biotechnology activities enhancing quality of life
10. Genetic engineering accelerates the impact of biotechnology on chemical production
11. Symposium to focus on ethical issues in biotechnology

Post Your Comments:
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) ... the Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer ... programs on May 30 at 1:30 p.m. Eastern Time.  A ... available on the Investors page of the Cleveland BioLabs website ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) ... are pleased to announce a sponsorship agreement with Erebus ... Zealand distributor of DrugCheck® onsite testing devices, manufactured by ... the Austin 400 May 17-19 in Austin, Texas. , ... involves each car of the Erebus Motorsport team displaying ...
(Date:5/22/2013)... Miami, FL (PRWEB) May 22, 2013 A ... effects of probiotics on athletes to find that those who ... percent longer. The results from the study showed that in ... Probiotic Action, known for their adult acne treatment ... acne, and how it may help their skin condition. ...
(Date:5/21/2013)... , May 22, 2013 First ... formulation of glycopyrronium bromide designed using Prosonix, particle engineering ... developing a portfolio of inhaled Respiratory Medicines by ... with PSX1002 that will assess its effect on lung ... in patients with moderate to severe chronic obstructive pulmonary ...
Breaking Biology Technology:Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: